Predictive polygenic score for outcome after first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis.
Park HA, Edelmann D, Canzian F et al.
Publication Details
Comprehensive information about this research publication
Abstract
Summary of the research findings
Associations between candidate germline genetic variants and treatment outcome of oxaliplatin, a drug commonly used for patients with colorectal cancer, have been reported but not robustly established. This study aimed to construct polygenic hazard scores (PHSs) as predictive markers for oxaliplatin treatment outcome by using a supervised principal component approach (PCA).
2,547 European ancestry cases with oxaliplatin treatment, 118 European ancestry cases with other treatment, 134 Asian ancestry cases with oxaliplatin treatment, 6 Asian ancestry cases with other treatment, 213 African American cases with oxaliplatin treatment, 7 African American cases with other treatment, 73 cases with oxaliplatin treatment
Study Statistics
Key metrics and study information
AI-Generated Summary
AI-generated by DNAGENICSIndependent AI summary of health and genetic findings from the published study
Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.
AI Summary In Progress
Our AI-generated summary of this publication is being prepared. Please check back soon.